Researchers at the University of Minnesota Twin Cities may have discovered a mechanical explanation for instability observed in the lungs in cases of acute respiratory distress syndrome (ARDS), particularly in the aftermath of respiratory illnesses such as COVID-19 or pneumonia.
AstraZeneca’s Fasenra to challenge GSK’s Nucala in rare vasculitis after FDA nod – Pharmaceutical Technology
Fasenra generated $1.55bn last year, according to AstraZeneca’s financials. Image credit: Alexanderstock23 / Shutterstock. AstraZeneca‘s Fasenra (bevacizumab) is set to challenge GSK’s Nucala (mepolizumab) in
September 19, 2024